KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Less is More? First Impressions From COSMIC-313.

Pavlos Msaouel

Cancer Invest 41(1) 101-106

PMID36239611
PMCIDPMC12309038
DOI10.1080/07357907.2022.2136681
发表日期2022-10-14
摘要

摘要

The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma. The first results presented at the 2022 European Society of Medical Oncology Congress are a milestone for the renal cell carcinoma field because they signal the advent of triplet combinations as potential treatment options for our patients. The present commentary highlights some considerations and potential next steps based on these first impressions.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。